Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 284-902-1 | CAS number: 84989-13-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Acute Toxicity: Oral: LD50 = >300 - <2,000 mg/kg bw; OECD 423; Anon., 2017
Acute Toxicity: Inahaltion: Waiver
Acute Toxicity: Dermal: LD50 = > 2,000 mg/kg bw; OECD 402; A Poole., 2018
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 25 April 2017 - 18 January 2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- Study was conducted in accordance with international guidelines and in accordance with GLP. All guideline validity criteria were met.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1100 (Acute Oral Toxicity)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- no
- Specific details on test material used for the study:
- RADIOLABELLING INFORMATION (if applicable)
- Radiochemical purity:
- Specific activity:
- Locations of the label:
- Expiration date of radiochemical substance:
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material:
- Stability under test conditions:
- Solubility and stability of the test substance in the solvent/vehicle:
- Reactivity of the test substance with the solvent/vehicle of the cell culture medium:
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing:
- Preliminary purification step (if any):
- Final dilution of a dissolved solid, stock liquid or gel:
- Final preparation of a solid:
FORM AS APPLIED IN THE TEST (if different from that of starting material)
OTHER SPECIFICS: - Species:
- rat
- Strain:
- other: Crl:WI(Han)
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River, Margate, UK
- Females (if applicable) nulliparous and non-pregnant: Yes
- Age at study initiation: 8-9 weeks
- Weight at study initiation: All within ±20 % of the mean value
- Fasting period before study: Yes, on the evening prior to dosing.
- Housing: The animals were housed in groups of up to five during the acclimatisation period in cages that conform to the 'Code of Practice for the Housing and Care of Animals Bred, Supplied or Used for Scientific Purposes’ (Home Office, London, 2014). From the day prior to dosing (Day-1), the rats were housed in groups of three in similar cages. Bedding was provided on a weekly basis to each cage by use of clean European soft wood bedding (Datesand Ltd., Manchester, UK). Each batch of bedding was analysed for specific constituents and contaminants. No contaminants were present in bedding at levels which might have interfered with achieving the objective of the study. Results are retained on file at Covance.
- Diet (e.g. ad libitum): Throughout the study the animals had access to 5LF2 EU Rodent Diet 14%, which was freely available to the animals at all times, except for a period of fasting from the evening of the day prior to dosing (Day-1) until approximately 3 hours after dosing. Each batch of diet had been analysed for specific constituents and contaminants by the manufacturer. No contaminants were present in diet at levels which might have interfered with achieving the objective of the study. Results are retained on file at Covance.
- Water (e.g. ad libitum): Mains water was provided ad libitum via cage mounted water bottles. The water was periodically analysed for specific contaminants. No contaminants were present in water at levels which might have interfered with achieving the objective of the study. Results are retained on file at Covance.
- Acclimation period: 7 to 10 days.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24 ºC
- Humidity (%): 45-65 %
- Air changes (per hr): 15-20
- Photoperiod (hrs dark / hrs light): 12:12
IN-LIFE DATES: From: 25 April 2017 To: 01 June 2017 - Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 30, 103 and 200 mg/mL for the 300. 1031 and 2000 mg/kg bw groups, respectively.
- Amount of vehicle (if gavage): 10 mL/kg bw
- Justification for choice of vehicle: n/a
- Lot/batch no. (if required): n/a
- Purity: n/a
MAXIMUM DOSE VOLUME APPLIED: 2000 mg/kg bw (applied from a 200 mg/mL formulation).
DOSAGE PREPARATION (if unusual): The test article was dispersed in purified water. The formulated concentrations were calculated from the selected dose level and the dose volume of 10 mL/kg. All formulations were used within two hours of preparation.
The formulations were either maintained on a magnetic stirrer or the dose containers repeatedly inverted prior to administration, to ensure homogeneity.
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: Maximum concentration as stipulated in OECD 423. - Doses:
- 2000, 1031 and 300 mg/kg bw
- No. of animals per sex per dose:
- 6 animals receievd the 300 mg/kg bw dose, groups of 3 animals each received 1031 and 2000 mg/kg bw. Dosing of the group at 1031 mg/kg bw was conducted in error, but does not impact the validity of the study.
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Treated rats were observed closely for clinical signs of reaction to treatment. Clinical signs were recorded immediately post-dose, at approximately 15 and 30 minutes post-dose, hourly between 1 and 4 hours post-dose (inclusive), twice daily on Days 2, 3 and 4 and once daily from the fifth to last day of the observation period. Individual records of clinical signs and times of death were maintained for each treated rat. Individual body weights were recorded on Day-1 (day before dosing) and on Days 1, 4, 8 and 15. Decedent carcass weights were also recorded prior to necropsy.
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight. - Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 300 - <= 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- Three animals treated at 2000 mg/kg and one animal treated at 1031 mg/kg were found dead one day after dosing. There were no deaths amongst animals treated at 300 mg/kg.
- Clinical signs:
- other: No clinical signs were seen in animals treated at 300 mg/kg. Common clinical signs seen in animals treated at 1031 or 2000 mg/kg were piloerection, hunched posture and decreased activity. The clinical signs developed from 30 minutes after dosing and last
- Gross pathology:
- No abnormalities were noted at necropsy of animals that died or were killed at the end of the study.
- Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- Based on the conditions of this study, the test article was classified as Category 4 in respect of its acute oral toxicity according to the Globally Harmonized System of Classification and Labelling of Chemicals (GHS).
- Executive summary:
OECD 423 (2017) - In an acute oral toxicity study (OECD 423), groups of fasted, 8-9 week old, female Crl:WI(Han) rats were given a single oral dose of Benzenesulfonicacid, 4 -C10 -13 -sec-alkyl derivs., ammonium salts at doses 2000, 1031 and 300 mg/kg bw and observed for 14 days.
Oral LD50 Females = >300 - 2000 mg/kg bw.
According to the UN GHS classification, the test item can be classified as Category 4 in respect of its acute oral toxicity.
Reference
Table 2 Mortality Data
Does Level (mg/kg) | Mortality Ratio | Time of Death after Dosing |
300 | 0/6 | |
1031 | 1/3 | Day 2 |
2000 | 3/3 | Day 2 |
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 500 mg/kg bw
- Quality of whole database:
- ATE cut-off value based on standard data requirements for this endpoint. The required study is of suitable key stdy quality.
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- the study does not need to be conducted because exposure of humans via inhalation is not likely taking into account the vapour pressure of the substance and/or the possibility of exposure to aerosols, particles or droplets of an inhalable size
- Justification for type of information:
- JUSTIFICATION FOR DATA WAIVING
The vapour pressure of the substance was determined to be < 3.2E-02 Pa, which renders inhalation exposure to this substance negligible, negating the need for an acute toxicity study via the inhalation route. This waiver is in accordance with REACH Annex VIII, Section 8.5.2, Column 2 and ECHA Guidance on Information Requirements and Chemical Safety Assessment, Chapter R7.a.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 03 July 2018 - 08 August 2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- Guideline study performed under GLP. All relevant validity criteria were met.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Version / remarks:
- 09 October 2017
- Deviations:
- yes
- Remarks:
- The deviation was considered to have not affected the integrity or validity of the study
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- fixed dose procedure
- Limit test:
- yes
- Specific details on test material used for the study:
- RADIOLABELLING INFORMATION (if applicable): N/A
- Radiochemical purity:
- Specific activity:
- Locations of the label:
- Expiration date of radiochemical substance:
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL:
- Storage condition of test material: At room temperature in the dark
- Stability under test conditions:
- Solubility and stability of the test substance in the solvent/vehicle:
- Reactivity of the test substance with the solvent/vehicle of the cell culture medium:
TREATMENT OF TEST MATERIAL PRIOR TO TESTING: Tested undiluted
- Treatment of test material prior to testing:
- Preliminary purification step (if any):
- Final dilution of a dissolved solid, stock liquid or gel:
- Final preparation of a solid:
FORM AS APPLIED IN THE TEST (if different from that of starting material): N/A
OTHER SPECIFICS: N/A - Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Envigo RMS (UK) Limited, Oxon, UK
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: 8 - 12 weeks
- Weight at study initiation: body weight variation did not exceed ±20% of the mean body weight at the start of treatment
- Fasting period before study: not specified
- Housing: individually housed in suspended solid floor polypropylene cages furnished with softwood flake bedding.
- Diet (e.g. ad libitum): free access to food (2014C Teklad Global Rodent diet supplied by Envigo RMS (UK) Limited, Oxon, UK)
- Water (e.g. ad libitum): free access to mains drinking water
- Acclimation period: minimum of 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 - 25 ºC
- Humidity (%): 30 - 70 %
- Air changes (per hr): minimum of 15 changes per hour
- Photoperiod (hrs dark / hrs light): 12 : 12
- Type of coverage:
- semiocclusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- TEST SITE
- Area of exposure: back and flanks of each animal were clipped free of hair.
- % coverage: Approximately 10% of total body surface
- Type of wrap if used: A piece of surgical gauze was placed over the treatment area and semi‑occluded with a piece of self‑adhesive bandage.
REMOVAL OF TEST SUBSTANCE
- the treated skin and surrounding hair wiped with cotton wool moistened with dimethyl sulfoxide to remove any residual test item.
- Time after start of exposure: 24 h
TEST MATERIAL
- Amount applied: 2000 mg/kg bw (no correction made for purity)
- Constant volume or concentration used: 1.049 g/mL - Duration of exposure:
- 24h
- Doses:
- Limit test - 1000 mg/kg bw
Main 2000 mg/kg bw - No. of animals per sex per dose:
- Limit test - 1
Main - 2 - Control animals:
- not required
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Clinical observations and mortality checks were conducted at approximately 0.5, 1, 2, 4, 6 hours and subsequently once daily for 14 days. Scoring and criteria were consistent with the Draize Draize. Individual bodyweight were recorded prior to application of the test item on Day -1 (before dosing) and on Days 0, 7 and 14.
- Necropsy of survivors performed: yes - Statistics:
- n/a
- Preliminary study:
- No effect observed
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- >= 2 000 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Mortality:
- There were no deaths
- Clinical signs:
- other: There were no signs of systemic toxicity.
- Gross pathology:
- No abnormalities were noted at necropsy.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Under the conditions of this study the dermal LD50 was established to exceed 2000 mg/kg bw in female Wistar (RccHan:WIST) strain rat. Applicant assessment indicates, under the conditions of this study, and according to the GHS criteria, the LD50 cut-off value was considered to be greater than 5000 mg/kg body weight.
- Executive summary:
A study was performed according to OECD TG 402; Acute Toxicity (Dermal) and in accordance with GLP to assess the acute dermal toxicity of the test substance in the Wistar (RccHan:WIST) strain rat. Initial test was conducted with semi-occlusive application of undiluted test item at 1000 mg/kg bw to the clipped skin of one animinal. this is then followed by application of a single dose of the test item at a dose level of 2000 mg/kg body weight for a duration of 24 hour under semi-occluded condition and sequent observation for 14 days.
There was no mortality during the study. There were no signs of system toxicity or abnormalities on necropsy. Two animals treated at a dose level of 2000 mg/kg showed body weight loss with the remaining animal showing an expected gain in body weight during the first week. Two animals treated at a dose level of 2000 mg/kg showed expected gains in body weight with the remaining animal showing no gain in body weight during the second week. The animal treated at a dose level of 1000 mg/kg showed an expected gain in body weight during the observation period.. Signs of dermal irritation noted included very slight to well defined erythema and very slight edema, scattered areas of blanching over the treatment site, scattered areas of dermal hemorrhage over the treatment site, thickening of the skin, hardened light brown colored scabs, scab cracking, scab undulating, scab lifting to reveal glossy skin, scab lifting edge to reveal dried blood, scab lifting at edges to reveal further deeper scabbing, small superficial scattered scabs, glossy skin, loss of skin flexibility and loss of skin elasticity. The dermal reactions prevented the accurate evaluation of erythema and edema at several time points.
Under the conditions of this study the dermal LD50 was established to exceed 2000 mg/kg bw in female Wistar (RccHan:WIST) strain rat. Applicant assessment indicates, under the conditions of this study, and according to the GHS criteria, the LD50 cut-off value was considered to be greater than 5000 mg/kg body weight.
Reference
Table 1. Dermal Reactions at Dose level 2000 mg/kg
Dose Level (mg/kg) |
Animal Number and Sex |
Observation |
Effects Noted After Initiation of Exposure |
|||||||||||||
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
|||
2000 |
2-0 |
Erythema |
2 |
2 |
1 |
0 |
?e |
?e |
?e |
?e |
?e |
?e |
?e |
?e |
?e |
?e |
Edema |
1 |
1 |
1 |
1 |
?od |
?od |
?od |
?od |
?od |
?od |
?od |
?od |
?od |
?od |
||
Other |
BlHd |
BlHdTh |
BlThSp |
BlThSp |
Sp |
SpSk |
SpSkSw |
SpSkSw |
SpSkSw |
SpSkSw |
SpSk |
SpSk |
SpSk |
SpSkSg |
||
3-0 |
Erythema |
1 |
2 |
2 |
2 |
?e |
?e |
?e |
?e |
?e |
?e |
?e |
?e |
?e |
?e |
|
Edema |
1 |
1 |
1 |
1 |
?od |
?od |
?od |
?od |
?od |
?od |
?od |
?od |
?od |
?od |
||
Other |
ThLf |
ThBl |
LfBlTh |
LfBlTh |
SpSw |
SpSw |
SpSw |
SpSw |
SpSw |
SpSw |
SpSw |
SpSw |
SpSwSk |
SsSgSk |
||
3-1 |
Erythema |
1 |
2 |
2 |
2 |
?e |
?e |
?e |
?e |
?e |
?e |
?e |
?e |
?e |
?e |
|
Edema |
1 |
1 |
1 |
1 |
?od |
?od |
?od |
?od |
?od |
?od |
?od |
?od |
?od |
?od |
||
Other |
ThLf |
ThBlLf |
ThBlLf |
ThBlLf |
SpSwSk |
SpSwSk |
SpSkSb |
SdSb |
SdSb |
SdSb |
SdSb |
SbSpSk |
SbSpSkSg |
SkSpSg |
0 = No reactions Hd = Dermal hemorrhage
Th = Thickening of the skin ?e = Dermal reactions prevented the accurate evaluation of erythema
Lf = Loss of skin flexibility ?od = Dermal reactions prevented the accurate evaluation of edema
Bl = Blanching of the skin Ss = Small superficial scattered scabs
Sp = Hardened brown colored scab
Sw = Scab undulating
Sk = Scab cracking
Sg = Scab lifting to revel glossy skin
Sb = Scab lifting at edges to reveal dried blood
Sd = Scab lifting to at edges to reveal further deeper scabbing
Table 2. Individual Body Weight Changes at Dose level 2000 mg/kg
Dose Level (mg/kg) |
Animal Number and Sex |
Body Weight (g) at Day |
Body Weight Change (g) During Week |
|||
0 |
7 |
14 |
1 |
2 |
||
2000 |
2-0 Female |
222 |
219 |
231 |
-3 |
12 |
3-0 Female |
229 |
232 |
232 |
3 |
0 |
|
3-1 Female |
232 |
229 |
232 |
-3 |
3 |
Table 3. Individual Necropsy Finding at Dose level 2000 mg/kg
Dose Level |
Animal Number and Sex |
Time of Death |
Macroscopic Observations |
2000 |
2-0 Female |
Killed Day 14 |
No abnormalities detected |
3-0 Female |
Killed Day 14 |
No abnormalities detected |
|
3-1 Female |
Killed Day 14 |
No abnormalities detected |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- The endpoint is concluded based on a single key study with a Klimisch rating of 1. No effects were observed up to the limit dose of 2000 mg/kg bw/day
Additional information
Acute Toxicity: Oral
OECD 423 (2017) - In an acute oral toxicity study (OECD 423) conducted on the registered substance, groups of fasted, 8-9 week old, female Crl:WI(Han) rats were given a single oral dose of Benzenesulfonicacid, 4 -C10 -13 -sec-alkyl derivs., ammonium salts at doses 2000 and 300 mg/kg bw and observed for 14 days. Oral LD50 Females = >300 - 2000 mg/kg bw. According to the UN GHS classification, the test item can be classified as Category 4 in respect of its acute oral toxicity.
Acute Toxicity: Inhalation
The vapour pressure of the substance was determined to be < 3.2E-02 Pa, which renders inhalation exposure to this substance negligible, negating the need for an acute toxicity study via the inhalation route. This waiver is in accordance with REACH Annex VIII, Section 8.5.2, Column 2 and ECHA Guidance on Information Requirements and Chemical Safety Assessment, Chapter R7.a..
Acute Toxicity: Dermal
OECD 402 (2018) - In an acute dermal toxicity study (OECD 402) conducted on the registered substance, groups of fasted, 8-9 week old, female Crl:WI(Han) rats were given a single dose of undiluted test item, Benzenesulfonicacid, 4 -C10 -13 -sec-alkyl derivs., ammonium salts at doses 2000 mg/kg bw and observed for 14 days. Oral LD50 Females = >2000 mg/kg bw. According to the UN GHS classification, the test item does not meet the classified with respect to acute dermal toxicity.
Justification for classification or non-classification
Acute oral toxicity - Oral LD50 Females = >300 - 2000 mg/kg bw. According to the UN GHS classification, the test item can be classified as Category 4 in respect of its acute oral toxicity.
The substance does not meet the classification criteria for acute dermal or acute inhalation toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.